臺灣博碩士論文加值系統

人類微小病毒B19 (B19V)已被證明與心臟疾病，如心肌炎、心包炎等相關。先前研究已發現將B19V-VP1u蛋白質免疫注射至Balb/c小鼠會造成心臟損傷，因此本研究將進一步探討B19-VP1u不同片段蛋白質對於Balb/c小鼠心臟之影響。結果發現相較於正常Balb/c小鼠對照組，B19V-VP1u蛋白則不僅會促進Balb/c小鼠左心室心臟基質金屬蛋白酶MMP9活性及MMP9蛋白質和發炎相關因子IL-1b及IL-6蛋白質的表現，並且透過MAPK 及 NF-kB 蛋白質訊息傳遞路徑。另外，心肌肥大蛋白與心肌梗塞蛋白表現也有顯著增加。在B19V-VP1u片段對Balb/c小鼠心臟之影響中結果發現以VP1u-A片段病毒蛋白影響最顯著，不僅會促進小鼠心臟MMP9和IL-6蛋白質表現，並且透過磷酸化P38 MAPK訊息傳遞路徑。另外也促進心肌肥大蛋白和心肌梗塞蛋白的表現。而在病理組織切片中也發現有免疫細胞浸潤的情形。

Human parvovirus B19 (B19V) has been shown to be associated with heart diseases such as myocarditis and pericarditis. Previous studies have found that immunization of B19V-VP1u protein into Balb/c mice causes heart damage, so this study will further explore the B19V protein and analyze the different fragments of B19-VP1u protein on the heart of Balb/c mice. The B19V-VP1u protein not only promoted the activity of matrix metalloproteinase MMP9 and the expression of MMP9 protein and inflammation-related proteins IL-1β and IL-6 in the left ventricle of Balb/c mice, but also through the MAPK and NFκB protein signaling pathways. In addition, the performance of cardiac hypertrophic protein and myocardial infarction protein also increased significantly. The effect of the B19V-VP1u fragment on the heart of Balb/c mice was further analyzed. It was found that the most significant effect of VP1u-A virus protein was not only promoted the expression of MMP9 and IL-6 protein in mouse heart, but also through the phosphorylation of P38 MAPK message delivery pathway. It also promotes the expression of cardiac hypertrophic protein and myocardial infarction protein. In pathological tissue sections, B19V-VP1u and VP1u-A viral proteins were found to cause immune cell infiltration in the heart of Balb/c mice.

中文摘要 - 1 -
Abstract - 2 -
壹、 緒論 - 3 -
一、 人類微小病毒B19 - 3 -
(一) B19的分子生物學 - 3 -
(二) B19感染的臨床症狀 - 5 -
(三) B19病毒的檢驗 - 6 -
(四) B19的感染預防及治療 - 7 -
二、 人類微小病毒結構蛋白獨立區域(VP1u) - 8 -
三、 感染病毒與心肌炎 - 9 -
四、 人類微小病毒B19與心肌炎 - 9 -
貳、 研究動機 - 13 -
參、 實驗材料與方法 - 14 -
肆、 結果 - 21 -
伍、 討論 - 27 -
陸、 參考文獻 - 31 -
柒、 圖表 - 38 -

1.E Cossart Y: A new particulate antigen present in serum, vol. 30; 1975.
2.Qiu J, Soderlund-Venermo M, Young NS: Human Parvoviruses. Clinical microbiology reviews 2017, 30(1):43-113.
3.Department of Microbiology HMRC, Cornell University Medical College, New York, New York 10021.: Parvovirus replication. 1990.
4.A.Servant-Delmasa FM: Update of the human parvovirus B19 biology Actualites sur la biologie du parvovirus B19. 2016.
5.Craig Corcoran DH, Jane Yeats and Heidi Smuts: Genetic Variants of Human Parvovirus B19 in South Africa: Cocirculation of Three Genotypes and Identification of a Novel Subtype of Genotype 1 2009.
6.Tewary SK, Zhao H, Deng X, Qiu J, Tang L: The human parvovirus B19 non-structural protein 1 N-terminal domain specifically binds to the origin of replication in the viral DNA. Virology 2014, 449:297-303.
7.Nuesch JPF, Corbau R, Tattersall P, Rommelaere J: Biochemical Activities of Minute Virus of Mice Nonstructural Protein NS1 Are Modulated In Vitro by the Phosphorylation State of the Polypeptide. Journal of Virology 1998, 72(10):8002-8012.
8.Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K: Human Parvovirus B19 Nonstructural (NS1) Protein Induces Apoptosis in Erythroid Lineage Cells. Journal of Virology 1998, 72(4):3018-3028.
9.Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T: Regulation of Tumor Necrosis Factor Alpha Promoter by Human Parvovirus B19 NS1 through Activation of AP-1 and AP-2. Journal of Virology 2002, 76(11):5395-5403.
10.Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, Warrener P, Bansal G, Collett MS: Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. Journal of Clinical Investigation 1992, 89(6):2023-2029.
11.Weigel-Kelley KA, Yoder MC, Srivastava A: Recombinant Human Parvovirus B19 Vectors: Erythrocyte P Antigen Is Necessary but Not Sufficient for Successful Transduction of Human Hematopoietic Cells. Journal of Virology 2001, 75(9):4110-4116.
12.Weigel-Kelley KA, Yoder MC, Srivastava A: α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry. Blood 2003, 102(12):3927.
13.Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T: Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005, 106(10):3449.
14.Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE: Molecular and Functional Analyses of a Human Parvovirus B19 Infectious Clone Demonstrates Essential Roles for NS1, VP1, and the 11-Kilodalton Protein in Virus Replication and Infectivity. Journal of Virology 2006, 80(12):5941-5950.
15.Chen AY, Zhang EY, Guan W, Cheng F, Kleiboeker S, Yankee TM, Qiu J: The small 11kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood 2010, 115(5):1070-1080.
16.Young NS, Brown KE: Parvovirus B19. New England Journal of Medicine 2004, 350(6):586-597.
17.Lamont RF, Sobel J, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Uldbjerg N, Romero R: Parvovirus B19 Infection in Human Pregnancy. BJOG : an international journal of obstetrics and gynaecology 2011, 118(2):175-186.
18.Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M: Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG: An International Journal of Obstetrics & Gynaecology 2005, 107(4):476-480.
19.Crane J, Mundle W, Boucoiran I, Gagnon R, Bujold E, Basso M, Bos H, Brown R, Cooper S, Gouin K et al: Parvovirus B19 Infection in Pregnancy, vol. 36; 2014.
20.Arabzadeh SAM, Alizadeh F, Tavakoli A, Mollaei H, Bokharaei-Salim F, Karimi G, Farahmand M, Mortazavi HS, Monavari SH: Human parvovirus B19 in patients with beta thalassemia major from Tehran, Iran. Blood research 2017, 52(1):50-54.
21.Heegaard ED, Rosthj S, Petersen BL, Nielsen S, Pedersen FK, Hornsleth A: Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Paediatrica 2007, 88(6):614-617.
22.Bogomolovas J, Simoliunas E, Rinkunaite I, Smalinskaite L, Podkopajev A, Bironaite D, Weis CA, Marx A, Bukelskiene V, Gretz N et al: A Novel Murine Model of Parvovirus Associated Dilated Cardiomyopathy Induced by Immunization with VP1-Unique Region of Parvovirus B19. BioMed research international 2016, 2016:1627184.
23.Bor-ShowTzang T-M, Chun-ChouTsaidJeng-DongHsu,Lien-ChuanYang,Tsai-ChingHsu: Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. 2011.
24.Hatakka A, Klein J, He R, Piper J, Tam E, Walkty A: Acute Hepatitis as a Manifestation of Parvovirus B19 Infection. Journal of Clinical Microbiology 2011, 49(9):3422-3424.
25.Besse W, Mansour S, Jatwani K, Nast CC, Brewster UC: Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation. BMC Nephrology 2016, 17(1):125.
26.Komatsuda A, Ohtani H, Nimura T, Yamaguchi A, Wakui H, Imai H, Miura AB: Endocapillary proliferative glomerulonephritis in a patient with parvovirus B19 infection. American Journal of Kidney Diseases 2000, 36(4):851-854.
27.Ferrari SM, Fallahi P, Antonelli A, Benvenga S: Environmental Issues in Thyroid Diseases. Frontiers in endocrinology 2017, 8:50.
28.Bozzola E, Krzysztofiak A, Cortis E: Neurological impairment and arthritis in an immunocompetent child with human parvovirus B19 chronic infection, vol. 18; 2010.
29.Hokynar K, Norja P, Laitinen H, Palomaki P, Garbarg-Chenon A, Ranki A, Hedman K, Soderlund-Venermo M: Detection and Differentiation of Human Parvovirus Variants by Commercial Quantitative Real-Time PCR Tests. Journal of Clinical Microbiology 2004, 42(5):2013-2019.
30.Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, Mortimer PP: Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1986, 24(4):522-526.
31.Lin CY, Chiu CC, Cheng J, Lin CY, Shi YF, Tsai CC, Tzang BS, Hsu TC: Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome. Virulence 2018, 9(1):208-216.
32.Tzang B-S, Chiu C-C, Tsai C-C, Lee Y-J, Lu IJ, Shi J-Y, Hsu T-C: Effects of human parvovirus B19 VP1 unique region protein on macrophage responses. Journal of Biomedical Science 2009, 16(1):13.
33.Tzang S, Tsay G, Lee Y-J, Li C, Sun Y-S, Hsu T-C: The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production, vol. 378; 2007.
34.Tzang B-S, Tsai C-C, Chiu C-C, Shi J-Y, Hsu T-C: Up-regulation of adhesion molecule expression and induction of TNF-α on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clinica Chimica Acta 2008, 395(1):77-83.
35.Chen D-Y, Tzang B-S, Chen Y-M, Lan J-L, Tsai C-C, Hsu T-C: The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clinica Chimica Acta 2010, 411(15):1084-1089.
36.Nie X, Zhang G, Xu D, Sun X, Li Z, Li X, Zhang X, He F, Li Y: The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scandinavian Journal of Infectious Diseases 2010, 42(2):121-128.
37.Di Filippo S: Improving outcomes of acute myocarditis in children. Expert Review of Cardiovascular Therapy 2016, 14(1):117-125.
38.Dennert R, Crijns HJ, Heymans S: Acute viral myocarditis. European Heart Journal 2008, 29(17):2073-2082.
39.Yajima T, Knowlton KU: Viral Myocarditis. Circulation 2009, 119(19):2615.
40.Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM et al: Association of Parvovirus B19 Genome in Children With Myocarditis and Cardiac Allograft Rejection. Circulation 1997, 96(10):3549.
41.Bock C-T, Klingel K, Kandolf R: Human Parvovirus B19–Associated Myocarditis. New England Journal of Medicine 2010, 362(13):1248-1249.
42.Corsten MF, Schroen B, Heymans S: Inflammation in viral myocarditis: friend or foe? Trends in Molecular Medicine 2012, 18(7):426-437.
43.Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S: Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. European journal of heart failure 2016, 18(12):1430-1441.
44.Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R et al: High Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated Left Ventricular Diastolic Dysfunction. Circulation 2005, 111(7):879.
45.Faure JM, Giacalone PL, Deschamps F, Boulot P: Nonimmune Hydrops fetalis Caused by Intrauterine Human Parvovirus B19 Infection: A Case of Spontaneous Reversal in utero. Fetal Diagnosis and Therapy 1997, 12(2):66-67.
46.Kuhl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP: Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. Journal of medical virology 2008, 80(7):1243-1251.
47.Zhang TAO, Miao WEI, Wang S, Wei MIN, Su G, Li Z: Acute myocarditis mimicking ST-elevation myocardial infarction: A case report and review of the literature. Experimental and Therapeutic Medicine 2015, 10(2):459-464.
48.Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y: Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology 2006, 45(suppl_4):iv8-iv13.
49.Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss H-P, Kuehl U, Modrow S: Adaptive immune responses against parvovirus B19 in patients with myocardial disease. Journal of Clinical Virology 2009, 44(1):27-32.
50.Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B: Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Human Pathology 2003, 34(5):497-503.
51.Pankuweit S, Lamparter S, Schoppet M, Maisch B: Parvovirus B19 Genome in Endomyocardial Biopsy Specimen. Circulation 2004, 109(14):e179.
52.Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT et al: Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis. Circulation 2006, 114(15):1581.
53.Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R: Fatal parvovirus B19–associated myocarditis clinically mimicking ischemic heart disease: An endothelial cell–mediated disease. Human Pathology 2003, 34(1):92-95.
54.Duechting A, Tschope C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R, Bock CT: Human Parvovirus B19 NS1 Protein Modulates Inflammatory Signaling by Activation of STAT3/PIAS3 in Human Endothelial Cells. Journal of Virology 2008, 82(16):7942-7952.
55.De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L: Myocarditis: An Interleukin-1-Mediated Disease? Frontiers in Immunology 2018, 9:1335.
56.Canaan S, Zadori Z, Ghomashchi F, Bollinger J, Sadilek M, Moreau ME, Tijssen P, Gelb MH: Interfacial Enzymology of Parvovirus Phospholipases A2. Journal of Biological Chemistry 2004, 279(15):14502-14508.
57.Zadori Z, Szelei J, Lacoste M-C, Li Y, Gariepy S, Raymond P, Allaire M, Nabi IR, Tijssen P: A Viral Phospholipase A2 Is Required for Parvovirus Infectivity. Developmental Cell 2001, 1(2):291-302.
58.Cihakova D, Rose NR: Chapter 4 Pathogenesis of Myocarditis and Dilated Cardiomyopathy. In: Advances in Immunology. vol. 99: Academic Press; 2008: 95-114.
59.Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D''Amati G, Koch WC, Adler SP: Human Parvovirus B19 Infection in Infancy Associated with Acute and Chronic Lymphocytic Myocarditis and High Cytokine Levels: Report of 3 Cases and Review. Clinical Infectious Diseases 2000, 31(1):65-69.
60.Klingel K, Sauter M, Bock CT, Szalay G, Schnorr J-J, Kandolf R: Molecular pathology of inflammatory cardiomyopathy. Medical Microbiology and Immunology 2004, 193(2):101-107.
61.Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN: Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19-Associated Chronic Fatigue Syndrome. Clinical Infectious Diseases 2003, 36(9):e100-e106.
62.Yokoseki O, Suzuki J-i, Kitabayashi H, Watanabe N, Wada Y, Aoki M, Morishita R, Kaneda Y, Ogihara T, Futamatsu H et al: cis Element Decoy Against Nuclear Factor-κB Attenuates Development of Experimental Autoimmune Myocarditis in Rats. Circulation Research 2001, 89(10):899.
63.Alter P, Rupp H, Maisch B: Activated nuclear transcription factor κB in patients with myocarditis and dilated cardiomyopathy—relation to inflammation and cardiac function. Biochemical and Biophysical Research Communications 2006, 339(1):180-187.
64.Xu T, Wu X, Chen Q, Zhu S, Liu Y, Pan D, Chen X, Li D: The Anti-Apoptotic and Cardioprotective Effects of Salvianolic Acid A on Rat Cardiomyocytes following Ischemia/Reperfusion by DUSP-Mediated Regulation of the ERK1/2/JNK Pathway. PLoS ONE 2014, 9(7):e102292.
65.Hu X, Wang H, Liu J, Fang X, Tao K, Wang Y, Li N, Shi J, Wang Y, Ji P et al: The role of ERK and JNK signaling in connective tissue growth factor induced extracellular matrix protein production and scar formation. Archives of Dermatological Research 2013, 305(5):433-445.
66.Muslin AJ: MAPK Signaling in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Targets. Clinical science (London, England : 1979) 2008, 115(7):203-218.
67.Kuhl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CPL, Seeberg B, Krautwurm L, Poller W, Schultheiss H-P, Kandolf R: Parvovirus B19 Infection Mimicking Acute Myocardial Infarction. Circulation 2003, 108(8):945.
68.A Servonnet HD, C Dehan, V Gardet: Un nouveau marqueur cardiaque : la heart fatty-acid binding protein (h-FABP). 2006, Volume 64,.
69.Arakawa N, Nakamura M, Endo H, Sugawara S, Suzuki T, Hiramori K: Brain Natriuretic Peptide and Cardiac Rupture after Acute Myocardial Infarction. Internal Medicine 2001, 40(3):232-236.
70.Gardner DG: Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends in Endocrinology & Metabolism 2003, 14(9):411-416.
71.Stephen A. Morris M, PhD, Drew Helmer,MD,† Michael Pesce,PhD, and James Giglio,MD: Clinical utility of CKMB isoform determinations in patients whopresent to the emergency department with continuous orresolved chest pain. . 2000.